The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The High Court of Justice of England and Wales has approved Eli Lilly's acquisition of Centessa Pharmaceuticals for $38.00 per share in cash. The total transaction value is approximately $7.8 billion, which includes contingent value rights (CVRs) of up to $9.00 per share based on the achievement of specific milestones. This judicial approval follows the definitive agreement reached on March 31, 2026, serving as the final legal requirement to formalize the merger of the clinical-stage biotech firm.
Sign in to access this content
Sign InThis acquisition occurs as major pharmaceutical players accelerate M&A activity to bolster their drug pipelines, with Eli Lilly maintaining a competitive stance against peers like Novo Nordisk in the metabolic and rare disease spaces. Per market data, the $38 offer reflects a strategic premium for Centessa's clinical assets. Industry analysts note that such deals are increasingly common as large-cap pharma companies deploy cash reserves to offset future revenue gaps from patent expirations.
Regarding market levels, LLY closed at $1,104.23 and CNTA at $40.02 (as of June 22, 2026). Investors should now watch for the formal delisting date of Centessa shares and updates on the operational integration of its research programs. Additionally, broader market sentiment may be influenced by upcoming macro catalysts, such as the Eurozone CPI release, which remains a key event on the economic calendar for global healthcare investors.